Posts

Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers

on
Sangamo Therapeutics has filed for Chapter 11 bankruptcy and will put substantially all of its assets up for sale through a court-supervised process. The company has lined up Eli Lilly and Astellas Pharma as "stalking horse" bidders for key assets, with Lilly targeting Sangamo's capsid delivery, zinc finger, and MINT genome‑editing platforms plus the prion disease program ST‑506, and Astellas targeting the Fabry disease gene therapy candidate isaralgagene civaparvovec (ST‑920). Sources: Sangamo to put 'substantially all' assets for sale in bankruptcy, lines ... Sangamo申请破产 基因治疗平台待售 礼来与安斯泰来正密切关注 Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle Chapter 11, asset sales and layoffs at Sangamo Therapeutics (SGMO) Form 10-Q for Sangamo Therapeutics INC filed 11/06/2025 [PDF] Form 424B5 for Sangamo Therapeutics INC filed 02/04/2026 Sangamo dépose le bilan et signe des accords de cession d’actifs avec Lilly Par Invest...

Pfizer's first new ADC from Seagen acquisition fails Phase 3 NSCLC trial but may live on in earlier lines and combinations

on

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

on

Federal health agencies unveil plan to speed up Phase 1 clinical trials by 6 to 12 months

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

Merck Posts Encouraging Phase 3 Ulcerative Colitis Data But Roche Challenge Looms

on

Nura Bio Raises $73.8M Series B to Advance SARM1 Inhibitors for Neurodegeneration

on

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Villya Announces Breakthrough Data Demonstrating Enhanced Stability and Solubility for Insulin, GLP-1s

on

Trace Neuroscience launches first global clinical program for TRCN‑1023 ASO in ALS

on

Definium's LSD Formula Produces Best Data Ever Seen in Pivotal Depression Trial, CEO Says

on

In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy

on